Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas

Annals of Oncology

Volumn 25, Issue 1, 2014, Pages 246-250

  Egberts, F ^a   Bergner, I ^a   Kruger S ^a   Haag, J ^a   Behrens, H M ^a   Hauschild, A ^a   Rocken C ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

BRAF; Genotype; Melanoma of unknown primary; Metastatic melanoma

Indexed keywords

B RAF KINASE;

ADULT; AGED; ARTICLE; BRAF GENE; CANCER GROWTH; CANCER OF UNKNOWN PRIMARY SITE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; CORRELATIONAL STUDY; CUTANEOUS MELANOMA; DISTANT METASTASIS; FEMALE; GENE MUTATION; GENOTYPE; HISTOLOGY; HUMAN; HUMAN TISSUE; KIT GENE; LYMPH NODE METASTASIS; MALE; METASTATIC MELANOMA; METASTATIC MELANOMA OF UNKNOWN PRIMARY; MULTIPLE CANCER; MUTATIONAL ANALYSIS; ONCOGENE N RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GENE;

BRAF; GENOTYPE; MELANOMA OF UNKNOWN PRIMARY; METASTATIC MELANOMA;

AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENOTYPE; GTP PHOSPHOHYDROLASES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; SKIN NEOPLASMS;

EID: 84896391295     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt411     Document Type: Article

References (22)

1. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-3648.
2. Curtin JA, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-2147.
3. Jakob JA, Bassett RL, Jr, Ng CS et al. NRAS Mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012; 118: 4014-4023.
4. Cohen Y, Rosenbaum E, Begum S et al. Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites. Clin Cancer Res 2004; 10: 3444-3447.
5. Curtin JA, Busam K, Pinkel D et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24: 4340-4346.
6. Omholt K, Grafstrom E, Kanter-Lewensohn L et al. KIT Pathway alterations in mucosal melanomas of the vulva and other sites. Clin Cancer Res 2011; 17: 3933-3942.
7. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
8. Warneke V, Behrens H, Haag J et al. Prognostic and putative predictive biomarkers of gastric cancer for personalized medicine. Diagn Mol Pathol 2013; 22: 127-137.
9. Kamposioras K, Pentheroudakis G, Pectasides D et al. Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature. Crit Rev Oncol Hematol 2011; 78: 112-126.
10. Lee CC, Faries MB, Wanek LA et al. Improved survival for stage IV melanoma from an unknown primary site. J Clin Oncol 2009; 27: 3489-3495.
11. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
12. Kefford R, Arkenau H, Brown MP et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 2010; 28(suppl 15s): abstr 8503.
13. Long GV, Kefford RF, Carr PJA et al. Phase 1/2 study OF GSK2118436, a selective inhibitor of V600 mutant (MUT) braf kinase: evidence of activity in melanoma brain metastases (METS). Ann Oncol 2010; 21.
14. Carvajal RD, Chapman PB, Wolchok JD et al. A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT. J Clin Oncol 2009; 27(suppl): abtr 9001.
15. Lee CC, Faries MB, Wanek LA et al. Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol 2008; 26: 535-541.
16. Long GV, Menzies AM, Nagrial AM et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29: 1239-1246.
17. Cormier JN, Xing Y, Feng L et al. Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer 2006; 106: 2012-2020.
18. Shinozaki M, Fujimoto A, Morton DL et al. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res 2004; 10: 1753-1757.
19. Bauer J, Büttner P, Murali R et al. BRAF Mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res 2011; 24: 345-351.
20. Menzies AM, Haydu LE, Visintin L et al. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 2012; 18: 3242-3249.
21. Ellerhorst JA, Greene VR, Ekmekcioglu S et al. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res 2011; 17: 229-235.
22. Ugurel S, Thirumaran RK, Bloethner S et al. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS One 2007; 2: e236.